Growth Hormone (GH) in Congenital Adrenal Hyperplasia
Growth Hormone (GH) in Congenital Adrenal Hyperplasia
Congenital adrenal hyperplasia (CAH) is a genetic rare disease, which alters the adrenal
 production of gluco and mineralo corticoids. The treatment consists in supplementing children
 using hydrocortisone. Despite care for these children has improve substantially across
 decades, short adult height still remains an important consequence of the disease. About 20 %
 of patients have an AH below 2 standard deviations compared to their expected height.

 In the OPALE model study, the investigators have collected data from a cohort of 496 French
 patients, born between 1970 and 1991 and with a known genotype. Using their age, sex, growth,
 disease, bone maturation and pubertal data, they have built a model which allows to predict
 their AH using data available at 8 years of age. This model has shown that the currently used
 formula to calculate the predicted AH (Bayley Pineau's method) is not applicable to children
 with CAH.

 In this project, the investigators plan to use the prediction model to compare the AH in
 patients who have received GH treatment to their predicted AH using the model.

 The hypothesis is that GH improves the AH in such patients. Existing cohorts have shown
 improved growth celerity, and growth expectation using the Bayley-Pineau formula), but this
 has not been shown on the actual AH.

 This study will allow to reinforce the investigators' hypothesis.
Inclusion Criteria:

 Patients with CAH, born between 1970 and 1998, having received GH treatment for a minimal
 one year duration.

 Exclusion Criteria:

 -  Patients with chronic any growth altering disease, Turner syndrome or other genetic
 anomaly; 8-year wrist Xray and adult height should be available to allow the use of
 the OPALE model prediction.